(Alliance News) - Verona Pharma PLC on Monday said data from Phase 2b trials showed that nebulized ensifentrine improved lung function in patients with chronic obstructive pulmonary disease.
The biopharmaceutical company focused on respiratory diseases said that, administered over four weeks, nebulized ensifentrine as monotherapy or added on to tiotropium - a long acting anti-muscarinic bronchodilator - improved lung function in moderate to severe COPD patients regardless of smoking status or history of chronic bronchitis.
The first part of the study saw 40 patients given a single dose of the formulation and led to promising results, with lung function increasing in those given the formulation.
Full results are expected in the first half of 2021.
Shares in Verona Pharma were trading 3.2% higher at 79.95 pence each on Monday morning in London.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.